Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 574

1.

The authors reply.

Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI.

Kidney Int. 2020 Jan;97(1):213-214. doi: 10.1016/j.kint.2019.09.027. No abstract available.

PMID:
31901342
2.

Epidemiology and Pathophysiology of Glomerular C4d Staining in Native Kidney Biopsies.

Drachenberg CB, Papadimitriou JC, Chandra P, Haririan A, Mendley S, Weir MR, Rubin MF.

Kidney Int Rep. 2019 Jul 30;4(11):1555-1567. doi: 10.1016/j.ekir.2019.07.015. eCollection 2019 Nov.

3.

Extravascular Lung Water Assessment by Ultrasound to Guide Dry Weight Changes: Ready for Prime Time?

Agarwal R, Toto RD, Weir MR.

Am J Kidney Dis. 2020 Jan;75(1):1-3. doi: 10.1053/j.ajkd.2019.09.004. Epub 2019 Nov 12. No abstract available.

PMID:
31732236
4.

Blood Pressure and Living Kidney Donors: A Clinical Perspective.

Rastogi A, Yuan S, Arman F, Simon L, Shaffer K, Kamgar M, Nobakht N, Bromberg JS, Weir MR.

Transplant Direct. 2019 Sep 19;5(10):e488. doi: 10.1097/TXD.0000000000000939. eCollection 2019 Oct.

5.

Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors.

Holscher CM, Haugen CE, Jackson KR, Garonzik Wang JM, Waldram MM, Bae S, Locke JE, Reed RD, Lentine KL, Gupta G, Weir MR, Friedewald JJ, Verbesey J, Cooper M, Segev DL, Massie AB.

Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1493-1499. doi: 10.2215/CJN.04020419. Epub 2019 Sep 19.

PMID:
31537534
6.

Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.

Edmonston D, Wojdyla D, Mehta R, Cai X, Lora C, Cohen D, Townsend RR, He J, Go AS, Kusek J, Weir MR, Isakova T, Pencina M, Wolf M; CRIC Study Investigators.

Am J Kidney Dis. 2019 Dec;74(6):771-781. doi: 10.1053/j.ajkd.2019.05.026. Epub 2019 Aug 21.

PMID:
31445926
7.

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.

Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI.

Kidney Int. 2019 Aug;96(2):489-504. doi: 10.1016/j.kint.2019.02.033. Epub 2019 Mar 21.

PMID:
31142441
8.

Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.

Weir MR.

Postgrad Med. 2019 Jun 5:1-9. doi: 10.1080/00325481.2019.1624582. [Epub ahead of print]

PMID:
31132013
9.

Therapeutic Potential of Newer Drugs for Treating Hyperkalemia.

Weir MR.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):787-788. doi: 10.2215/CJN.04750419. Epub 2019 May 20. No abstract available.

PMID:
31110052
10.

Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies.

Weir MR.

J Diabetes. 2019 Jul;11(7):619-622. doi: 10.1111/1753-0407.12929. Epub 2019 May 7. No abstract available.

PMID:
31066238
11.

Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease.

Ku E, Hsu RK, Tuot DS, Bae SR, Lipkowitz MS, Smogorzewski MJ, Grimes BA, Weir MR.

J Am Heart Assoc. 2019 May 7;8(9):e011013. doi: 10.1161/JAHA.118.011013.

12.

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline.

Kramer HJ, Townsend RR, Griffin K, Flynn JT, Weiner DE, Rocco MV, Choi MJ, Weir MR, Chang TI, Agarwal R, Beddhu S.

Am J Kidney Dis. 2019 Apr;73(4):437-458. doi: 10.1053/j.ajkd.2019.01.007.

PMID:
30905361
13.

Hypertension in CKD: Core Curriculum 2019.

Ku E, Lee BJ, Wei J, Weir MR.

Am J Kidney Dis. 2019 Jul;74(1):120-131. doi: 10.1053/j.ajkd.2018.12.044. Epub 2019 Mar 19. Review.

PMID:
30898362
14.

Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease.

Chen J, Bundy JD, Hamm LL, Hsu CY, Lash J, Miller ER 3rd, Thomas G, Cohen DL, Weir MR, Raj DS, Chen HY, Xie D, Rao P, Wright JT Jr, Rahman M, He J.

Hypertension. 2019 Apr;73(4):785-793. doi: 10.1161/HYPERTENSIONAHA.118.12358.

PMID:
30776971
15.

Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.

Bajaj A, Xie D, Cedillo-Couvert E, Charleston J, Chen J, Deo R, Feldman HI, Go AS, He J, Horwitz E, Kallem R, Rahman M, Weir MR, Anderson AH, Rader DJ; CRIC Study Investigators.

Am J Kidney Dis. 2019 Jun;73(6):827-836. doi: 10.1053/j.ajkd.2018.11.010. Epub 2019 Jan 25.

16.

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants.

Weir MR, Kreutz R.

Mayo Clin Proc. 2018 Oct;93(10):1503-1519. doi: 10.1016/j.mayocp.2018.06.018. Review.

17.

Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.

Weir MR, Lakkis JI, Jaar B, Rocco MV, Choi MJ, Kramer HJ, Ku E.

Am J Kidney Dis. 2018 Dec;72(6):873-884. doi: 10.1053/j.ajkd.2018.06.010. Epub 2018 Sep 7. Review.

PMID:
30201547
18.

Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.

Weiner DE, Park M, Tighiouart H, Joseph AA, Carpenter MA, Goyal N, House AA, Hsu CY, Ix JH, Jacques PF, Kew CE, Kim SJ, Kusek JW, Pesavento TE, Pfeffer MA, Smith SR, Weir MR, Levey AS, Bostom AG.

Am J Kidney Dis. 2019 Jan;73(1):51-61. doi: 10.1053/j.ajkd.2018.05.015. Epub 2018 Jul 20.

19.

Obesity and Kidney Disease.

Lakkis JI, Weir MR.

Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):157-167. doi: 10.1016/j.pcad.2018.07.005. Epub 2018 Jul 5. Review.

PMID:
29981350
20.

The Reply.

Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn PV, Liu J, Claggett B, Monaco AP.

Am J Med. 2018 Aug;131(8):e349-e351. doi: 10.1016/j.amjmed.2018.04.003. Epub 2018 Jun 19. No abstract available.

PMID:
29934217
21.

Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.

Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA.

ESC Heart Fail. 2018 Aug;5(4):592-602. doi: 10.1002/ehf2.12292. Epub 2018 May 16.

22.

Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial.

Weinrauch LA, Claggett B, Liu J, Finn PV, Weir MR, Weiner DE, D'Elia JA.

Int J Nephrol Renovasc Dis. 2018 Apr 27;11:155-164. doi: 10.2147/IJNRD.S161001. eCollection 2018.

23.

Effectiveness of informational decision aids and a live donor financial assistance program on pursuit of live kidney transplants in African American hemodialysis patients.

Boulware LE, Ephraim PL, Ameling J, Lewis-Boyer L, Rabb H, Greer RC, Crews DC, Jaar BG, Auguste P, Purnell TS, Lamprea-Monteleagre JA, Olufade T, Gimenez L, Cook C, Campbell T, Woodall A, Ramamurthi H, Davenport CA, Choudhury KR, Weir MR, Hanes DS, Wang NY, Vilme H, Powe NR.

BMC Nephrol. 2018 May 3;19(1):107. doi: 10.1186/s12882-018-0901-x.

24.

Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).

Townsend RR, Anderson AH, Chirinos JA, Feldman HI, Grunwald JE, Nessel L, Roy J, Weir MR, Wright JT Jr, Bansal N, Hsu CY; CRIC Study Investigators.

Hypertension. 2018 Jun;71(6):1101-1107. doi: 10.1161/HYPERTENSIONAHA.117.10648. Epub 2018 Apr 30.

25.

Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation.

Berger JS, Peterson E, LalibertÉ F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir MR.

J Card Fail. 2019 Jun;25(6):436-447. doi: 10.1016/j.cardfail.2018.03.012. Epub 2018 Mar 27.

26.

Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J.

J Am Coll Cardiol. 2018 Mar 27;71(12):1379-1390. doi: 10.1016/j.jacc.2018.01.047. Epub 2018 Mar 10. Review.

27.

Hyperkalemia in the Hypertensive Patient.

Lakkis JI, Weir MR.

Curr Cardiol Rep. 2018 Mar 1;20(2):12. doi: 10.1007/s11886-018-0954-2. Review.

PMID:
29492706
28.

Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease.

Rahman M, Hsu JY, Desai N, Hsu CY, Anderson AH, Appel LJ, Chen J, Cohen DL, Drawz PE, He J, Qiang P, Ricardo AC, Steigerwalt S, Weir MR, Wright JT Jr, Zhang X, Townsend RR; CRIC Study Investigators.

Clin J Am Soc Nephrol. 2018 Apr 6;13(4):585-595. doi: 10.2215/CJN.08620817. Epub 2018 Feb 23.

29.

Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Mindikoglu AL, Opekun AR, Mitch WE, Magder LS, Christenson RH, Dowling TC, Weir MR, Seliger SL, Howell CD, Raufman JP, Rana A, Goss JA, Khaderi SA, Vierling JM.

Dig Dis Sci. 2018 Mar;63(3):665-675. doi: 10.1007/s10620-017-4897-z. Epub 2018 Feb 1.

30.

Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results.

Weinrauch LA, Liu J, Claggett B, Finn PV, Weir MR, D'Elia JA.

Int J Nephrol Renovasc Dis. 2017 Dec 22;11:1-7. doi: 10.2147/IJNRD.S148517. eCollection 2018.

31.

Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis.

Mindikoglu AL, Opekun AR, Putluri N, Devaraj S, Sheikh-Hamad D, Vierling JM, Goss JA, Rana A, Sood GK, Jalal PK, Inker LA, Mohney RP, Tighiouart H, Christenson RH, Dowling TC, Weir MR, Seliger SL, Hutson WR, Howell CD, Raufman JP, Magder LS, Coarfa C.

Transl Res. 2018 May;195:25-47. doi: 10.1016/j.trsl.2017.12.002. Epub 2017 Dec 12.

32.

Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
.

Weir MR, Haskell L, Berger JS, Ashton V, Laliberté F, Crivera C, Brown K, Lefebvre P, Schein J.

Clin Nephrol. 2018 May;89(5):314-329. doi: 10.5414/CN109281.

PMID:
29231162
33.

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.

Weir MR, Bushinsky DA, Benton WW, Woods SD, Mayo MR, Arthur SP, Pitt B, Bakris GL.

Am J Med. 2018 May;131(5):555-564.e3. doi: 10.1016/j.amjmed.2017.11.011. Epub 2017 Nov 26.

34.

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.

Weir MR, Pergola PE, Agarwal R, Fink JC, Kopyt NP, Singh AK, Kumar J, Schmitt S, Schaffar G, Rudy A, McKay JP, Kanceva R.

Am J Nephrol. 2017;46(5):364-370. doi: 10.1159/000481736. Epub 2017 Oct 30.

PMID:
29084409
35.

Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.

Pergola PE, Spiegel DM, Warren S, Yuan J, Weir MR.

Am J Nephrol. 2017;46(4):323-332. doi: 10.1159/000481270. Epub 2017 Oct 11.

36.

Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial.

Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn PV, Liu J, Claggett B, Monaco AP.

Am J Med. 2018 Feb;131(2):165-172. doi: 10.1016/j.amjmed.2017.08.038. Epub 2017 Sep 21.

PMID:
28943384
37.

The Author Replies.

Weir MR.

Kidney Int. 2017 Oct;92(4):1016-1017. doi: 10.1016/j.kint.2017.05.029. No abstract available.

PMID:
28938939
38.

Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial.

Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn P, Liu J, Claggett B, Monaco AP.

Int J Nephrol Renovasc Dis. 2017 Aug 18;10:233-242. doi: 10.2147/IJNRD.S139901. eCollection 2017.

39.

Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.

Kalil RS, Carpenter MA, Ivanova A, Gravens-Mueller L, John AA, Weir MR, Pesavento T, Bostom AG, Pfeffer MA, Hunsicker LG.

Am J Kidney Dis. 2017 Dec;70(6):762-769. doi: 10.1053/j.ajkd.2017.06.013. Epub 2017 Aug 9.

PMID:
28801121
40.

Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations.

Snitker S, Doerfler RM, Soliman EZ, Deo R, St Peter WL, Kramlik S, Fischer MJ, Navaneethan S, Delafontaine P, Jaar BG, Ojo A, Makos GK, Slaven A, Weir MR, Zhan M, Fink JC; for CRIC Study Investigators.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1409-1417. doi: 10.2215/CJN.12991216. Epub 2017 Aug 9.

41.

Habitual sleep and kidney function in chronic kidney disease: the Chronic Renal Insufficiency Cohort study.

Knutson KL, Lash J, Ricardo AC, Herdegen J, Thornton JD, Rahman M, Turek N, Cohan J, Appel LJ, Bazzano LA, Tamura MK, Steigerwalt SP, Weir MR, Van Cauter E; Cric Study Investigators.

J Sleep Res. 2018 Apr;27(2):281-289. doi: 10.1111/jsr.12573. Epub 2017 Jun 23.

42.

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.

Weir MR, Berger JS, Ashton V, Laliberté F, Brown K, Lefebvre P, Schein J.

Curr Med Res Opin. 2017 Oct;33(10):1891-1900. doi: 10.1080/03007995.2017.1339674. Epub 2017 Jul 11.

PMID:
28590785
43.

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers.

Lesko LJ, Offman E, Brew CT, Garza D, Benton W, Mayo MR, Romero A, Du Mond C, Weir MR.

J Cardiovasc Pharmacol Ther. 2017 Sep;22(5):434-446. doi: 10.1177/1074248417691135. Epub 2017 Feb 13.

44.

Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial.

Rajagopalan S, Alaiti MA, Broadwater K, Goud A, Gaztanaga J, Connelly K, Fares A, Shirazian S, Kreatsoulas C, Farkouh M, Dobre M, Fink JC, Weir MR.

Clin Cardiol. 2017 Sep;40(9):633-640. doi: 10.1002/clc.22718. Epub 2017 May 26.

45.

Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure.

Rafique Z, Weir MR, Onuigbo M, Pitt B, Lafayette R, Butler J, Lopes M, Farnum C, Peacock WF.

J Manag Care Spec Pharm. 2017 Apr;23(4-a Suppl):S10-S19. doi: 10.18553/jmcp.2017.23.4-a.s10.

46.

Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort.

Afshinnia F, Rajendiran TM, Karnovsky A, Soni T, Wang X, Xie D, Yang W, Shafi T, Weir MR, He J, Brecklin CS, Rhee EP, Schelling JR, Ojo A, Feldman H, Michailidis G, Pennathur S.

Kidney Int Rep. 2016 Nov;1(4):256-268. doi: 10.1016/j.ekir.2016.08.007. Epub 2016 Aug 18. Erratum in: Kidney Int Rep. 2017 Sep 18;2(6):1265.

47.

Histological Evolution of BK Virus-Associated Nephropathy: Importance of Integrating Clinical and Pathological Findings.

Drachenberg CB, Papadimitriou JC, Chaudhry MR, Ugarte R, Mavanur M, Thomas B, Cangro C, Costa N, Ramos E, Weir MR, Haririan A.

Am J Transplant. 2017 Aug;17(8):2078-2091. doi: 10.1111/ajt.14314. Epub 2017 Jun 6.

48.

Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Grams ME, Yang W, Rebholz CM, Wang X, Porter AC, Inker LA, Horwitz E, Sondheimer JH, Hamm LL, He J, Weir MR, Jaar BG, Shafi T, Appel LJ, Hsu CY; CRIC Study Investigators.

Am J Kidney Dis. 2017 Sep;70(3):337-346. doi: 10.1053/j.ajkd.2017.01.050. Epub 2017 Mar 30.

49.

Cell-Free DNA and Active Rejection in Kidney Allografts.

Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, Mannon RB, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen D, Weir MR, Hiller D, Prasad P, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Brennan DC; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators.

J Am Soc Nephrol. 2017 Jul;28(7):2221-2232. doi: 10.1681/ASN.2016091034. Epub 2017 Mar 9.

50.

Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications.

Weir MR.

Kidney Int. 2017 Mar;91(3):529-531. doi: 10.1016/j.kint.2016.11.019.

PMID:
28202167

Supplemental Content

Support Center